Metastatic Castration Resistant Prostate Cancer (MCRPC)

Clinical trials for patients diagnosed with metastatic prostate cancer that no longer responds to androgen deprivation treatment. (Stage 4)

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.

NCT Number: NCT05946824
Phase: PHASE2
Trial Summary: There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Celcuity Inc
Acronym: DASBRT-RPC

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

NCT Number: NCT05988918
Phase: PHASE2
Trial Summary: This protocol will enroll patients with pancreatic adenocarcinoma and adenosquamous carcinoma (Cohort 1), gastrointestinal/pancreatic neuroendocrine neoplasms with Ki-67 > 20% (Cohort 2) and neuroend – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Michigan Rogel Cancer Center
Acronym:

A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy

NCT Number: NCT06044025
Phase: PHASE1
Trial Summary: The goal of this clinical trial is to assess the feasibility of adding a combination of metformin and turmeric as part of a nutritional intervention regimen to the current standard of care, namely, in – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Arkansas
Acronym:

EMBRACE: Exercising Together

NCT Number: NCT06049355
Phase: PHASE2
Trial Summary: This phase II trial tests how well an exercise intervention, Exercising Together, works in preventing declines in physical and mental health in couples during radiation treatment for cancer. Treatment – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fusion Pharmaceuticals Inc.
Acronym:

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

NCT Number: NCT06066437
Phase: PHASE1|PHASE2
Trial Summary: To learn if the proposed dose of 177Lu rhPSMA-10.1 is safe. Phase 2 will open if the Phase 1 dose is found to be safe. To learn about the safety and effects of 177Lu rhPSMA-10.1 alone and with androg – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): M.D. Anderson Cancer Center
Acronym:

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT Number: NCT05939414
Phase: PHASE3
Trial Summary: The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after defini – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Novartis Pharmaceuticals
Acronym: PSMA-DC

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

NCT Number: NCT05125016
Phase: Phase 1|Phase 2
Trial Summary: To assess the safety, tolerability, and pharmacokinetics (PK) and to determine recommended phase 2 dosing regimen (RP2DR) of REGN4336 separately as monotherapy or in combination wi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Regeneron Pharmaceuticals
Acronym:

18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study

NCT Number: NCT05707182
Phase: EARLY_PHASE1
Trial Summary: The purpose of this study is to investigate the usefulness of PET/MRI with an investigational radioactive drug, 18F-rhPSMA-7.3, and MRI contrast in evaluating patients with prostate cancer eligible fo – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Alabama at Birmingham
Acronym:

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

NCT Number: NCT05726292
Phase: PHASE2
Trial Summary: Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as h – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Chicago
Acronym:

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

NCT Number: NCT05799248
Phase: PHASE3
Trial Summary: Study Title: Role of rhPSMA-7.3 PET/CT imaging in men with High-Risk prostate cancer following conventional imaging and associated changes in medical management Protocol number: BED-IIT-437 Phase: 3b – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): MidLantic Urology
Acronym:

Study in Patients With Advanced Cancers Associated With Expression of DLL3

NCT Number: NCT04471727
Phase: Phase 1|Phase 2
Trial Summary: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab i – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acronym:

CV CARE: CardioVascular Care in PC Patients

NCT Number: NCT06202820
Phase: NA
Trial Summary: This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with th – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym:

A Trial for a Preliminary Estimate of the Effectiveness of a Novel Theoretical Framework

NCT Number: NCT06461416
Phase: NA
Trial Summary: Aim 1: To determine the preliminary effect sizes of al ActiveHeal EST (Engage-Sustain-Triumph) Program on occupational resilience. – clinicaltrials.gov for more information and locations
* Aim 2: To determine the preliminary effect sizes of ActiveHeal ES – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Arkansas
Acronym:

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

NCT Number: NCT06457919
Phase: PHASE1|PHASE2
Trial Summary: The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Memorial Sloan Kettering Cancer Center
Acronym:

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer

NCT Number: NCT05818683
Phase: clinical trials
Trial Summary: The purpose of this study is to identify the recommended phase 2 doses (RP2Ds) of JNJ-78278343 with cetrelimab (JNJ-63723283) in Part 1 (dose escalation) and to determine safety at the RP2D(s) in Part – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Phase 1
Acronym:

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

NCT Number: NCT05398302
Phase: PHASE1
Trial Summary: This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): 858 Therapeutics, Inc.
Acronym:

Study of Oral MRT-2359 in Selected Cancer Patients

NCT Number: NCT05546268
Phase: PHASE1|PHASE2
Trial Summary: This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high- – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

NCT Number: NCT06318273
Phase: PHASE1
Trial Summary: Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of this study is to assess safety, pharmacokinetics, and – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): AbbVie
Acronym:

Study of INKmune in Patients With mCRPC (CaRe Prostate)

NCT Number: NCT06056791
Phase: PHASE1|PHASE2
Trial Summary: This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The st – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Inmune Bio, Inc.
Acronym: CaRe

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

NCT Number: NCT06193486
Phase: PHASE1
Trial Summary: This is a phase 1 single center clinical trial for patients with end stage Metastatic Castration Resistant Prostate Cancer who have progressed through standard of care treatment options and are on zol – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute
Acronym:

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk

NCT Number: NCT06237179
Phase: PHASE1|PHASE2
Trial Summary: To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak & 6-minute walk distance [6MWD]) among prostate cancer (PC) patients – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Virginia Commonwealth University
Acronym: EXTRA-PC

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT Number: NCT06242470
Phase: PHASE1
Trial Summary: The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): MacroGenics
Acronym:

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

NCT Number: NCT06257758
Phase: PHASE1|PHASE2
Trial Summary: The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers. There are two part – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Valerio Therapeutics
Acronym:

Study of AZD0754 in Participants With Metastatic Prostate Cancer

NCT Number: NCT06267729
Phase: PHASE1|PHASE2
Trial Summary: The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer. – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): AstraZeneca
Acronym: APOLLO

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

NCT Number: NCT05000294
Phase: Phase 1| Phase 2
Trial Summary: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective tr – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): University of Florida
Acronym:

Total Body PET-CT Imaging of Prostate Cancer Using Illuccix

NCT Number: NCT05558956
Phase: Early Phase 1
Trial Summary: Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning pro – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): BAMF Health
Acronym:

64Cu-GRIP B in Patients With Advanced Malignancies

NCT Number: NCT05888532
Phase: PHASE1|PHASE2
Trial Summary: This is a first-in-human phase I/II imaging study of 64Cu-GRIP B PET in patients with advanced genitourinary (GU) malignancies. The tracer is designed to detect extracellular granzyme B as it is secre – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Rahul Aggarwal
Acronym:

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

NCT Number: NCT05413850
Phase: Phase 1|Phase 2
Trial Summary: To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Blue Earth Therapeutics Ltd
Acronym:

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

NCT Number: NCT05081193
Phase: Phase 2
Trial Summary: Previous studies of high dose testosterone therapy given intramuscularly to men with metastatic castrate resistant prostate cancer suggest that high serum levels of testosterone ma – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acronym:

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

NCT Number: NCT05245006
Phase: Phase 1
Trial Summary: CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study is – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Robert Flavell, MD, PhD
Acronym:

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

NCT Number: NCT04703920
Phase: Phase 1
Trial Summary: This Phase 1 dose-escalation trial is to determine the safety, tolerability and recommended phase 2 dose of talazoparib in combination with belinostat in subjects with Metastatic B – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Michigan Rogel Cancer Center
Acronym:

Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

NCT Number: NCT04946370
Phase: Phase 1|Phase 2
Trial Summary: This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that i – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym:

Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer and Other Tumors

NCT Number: NCT03972657
Phase: Phase 1|Phase 2
Trial Summary: The primary objectives of the study in Dose Escalation are to evaluate safety, tolerability, and pharmacokinetics (PK) of REGN5678 alone and in combination with cemiplimab and in D – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Regeneron Pharmaceuticals
Acronym:

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

NCT Number: NCT05067140
Phase: Phase 1|Phase 2
Trial Summary: A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth in men with metastatic castration-resistant prostate cancer who have progressed on prior approved sy – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Arvinas Androgen Receptor, Inc.
Acronym:

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

NCT Number: NCT04363164
Phase: Phase 2
Trial Summary: Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acronym:

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

NCT Number: NCT04337580
Phase: Phase 2
Trial Summary: The purpose of this research study is to find out what effects (good and bad) omeprazole and cabazitaxel, or omeprazole and docetaxel, has on participants and their condition. Inve – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Wake Forest University Health Sciences
Acronym: FASN

The Genomic Medicine at VA Study

NCT Number: NCT04331535
Phase: Not Applicable
Trial Summary: This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Boston VA Research Institute, Inc.
Acronym: GenoVA

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT Number: NCT04585750
Phase: Phase 1|Phase 2
Trial Summary: This study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 alone and in combination with pembrolizumab in participants with advanced solid tumors containing a TP5 – clinicaltrials.gov for more information and locations and locations
Clinicaltrials.gov
Trial Sponsor(s): PMV Pharmaceuticals, Inc
Acronym:

Video Education With Result Dependent dIsclosure

NCT Number: NCT05225428
Phase: Not Applicable
Trial Summary: The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym: VERDI

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer

NCT Number: NCT05471414
Phase: Not Applicable
Trial Summary: The study is comparing the effect on weight of providing home-delivered whole-food, plant-based meals versus standard, general nutritional counseling to men with prostate cancer on androgen-deprivatio – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym: WFPBD

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideâ„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

NCT Number: NCT03129139
Phase: Phase 1
Trial Summary: A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Minneamrita Therapeutics LLC
Acronym: Minnelide 101

African Cancer Genome: GMD

NCT Number: NCT05754658
Phase:
Trial Summary: he goal of this study is to develop a comprehensive characterization of genetic and molecular drivers of breast and prostate cancer in individuals of – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fox Chase Cancer Center
Acronym:

Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy

NCT Number: NCT05869682
Phase: PHASE2
Trial Summary: This phase II trial tests how well bright white light (BWL) therapy works in reducing cancer-related fatigue and depression in patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant pa – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): City of Hope Medical Center
Acronym:

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

NCT Number: NCT05743621
Phase: PHASE1
Trial Summary: The purpose of this study is to determine what effects (good and bad) Enzalutamide and TVB-2640 have in the treatment of prostate cancer whose prostate cancer has spread to other parts of their body a – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym:

Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

NCT Number: NCT06039371
Phase: PHASE2
Trial Summary: This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment in patients with prostate cancer – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Washington
Acronym:

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

NCT Number: NCT06084338
Phase: PHASE2
Trial Summary: This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA ta – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): VA Office of Research and Development
Acronym:

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

NCT Number: NCT06100705
Phase: PHASE2
Trial Summary: This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Yale University
Acronym:

Study of MK-5684 Versus Alternative NHA in mCRPC (MK-5684-003)

NCT Number: NCT06136624
Phase: PHASE3
Trial Summary: This is a phase 3, randomized, open-label study of MK-5684 compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Merck Sharp & Dohme LLC
Acronym:

A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT Number: NCT06136650
Phase: PHASE3
Trial Summary: The purpose of this study is to assess the efficacy and safety of MK-5684 plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metast – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Merck Sharp & Dohme LLC
Acronym:

A Dose Finding Study to Treat Bone Tumor(s)

NCT Number: NCT06008483
Phase: PHASE1
Trial Summary: To determine the Maximum Tolerated Dose (MTD) of CycloSam®, Samarium-153-DOTMP (Sm-153-DOTMP), a radiopharmaceutical that delivers radiation to the bone when injected, given as a tandemly administere – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): QSAM Therapeutics, Inc.
Acronym:

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

NCT Number: NCT05682443
Phase: PHASE1|PHASE2
Trial Summary: The goal of this clinical trial is to examine the safety and efficacy of ONC-392 in combination with lutetium Lu 177 vipivotide tetraxetan in metastatic castration resistant prostate cancer patient wh – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): OncoC4, Inc.
Acronym: PRESERVE-006

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Patient Summary
NCT Number: NCT05848011
Phase: PHASE2
Trial Summary: The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic castration-resistant prostate cancer (MCRPC) who received – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:

A Study of DB-1311 in Advanced/Metastatic Solid Tumors

NCT Number: NCT05914116
Phase: PHASE1|PHASE2
Trial Summary: This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311 in subjects with advanced solid tumors. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:

A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

NCT Number: NCT04104893
Phase: Phase 2
Trial Summary: The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) char – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym: CHOMP

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

NCT Number: NCT05501548
Phase: PHASE2
Trial Summary: This is a study to evaluate the safety and clinical activity of the combination of olaparib and high-dose IV ascorbate, as second or later line of therapy, in castration resistant prostate cancer pati – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acronym:

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

NCT Number: NCT05633160
Phase: PHASE1|PHASE2
Trial Summary: The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer i – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Clarity Pharmaceuticals Ltd
Acronym: COMBAT

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT Number: NCT05613894
Phase: PHASE1
Trial Summary: This is an open-label, phase 1b dose-escalation study of cabozantinib in combination with 177Lu-PSMA-617 in subjects with mCRPC. The primary hypothesis is that cabozantinib with 177Lu-PSMA will be saf – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Utah
Acronym: CaboLu

Collection of Blood From Patients With Cancer

NCT Number: NCT00034216
Phase:
Trial Summary: This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and ol – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:

National Cancer Institute “Cancer Moonshot Biobank”

NCT Number: NCT04314401
Phase:
Trial Summary: This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The “Cancer Moonshot Biobank” is a longitudinal study. This means it collects and stores sa – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

NCT Number: NCT04995198
Patient Summary
Phase:
Trial Summary: PROMISE aims to create a comprehensive nationwide registry of prostate cancer patients with germline pathogenic variants by prospectively screening approximately 5,000 subjects with a confirmed prostate cancer diagnosis, either through tissue biopsy, PSA greater than 100 ng/dL and/or radiographic evidence of disease and receiving systemic therapy for prostate cancer. Patients at all stages of disease will be welcome to participate in the PROMISE Registry. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Prostate Cancer Clinical Trials Consortium
Acronym:

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

NCT Number: NCT05805371
Phase: PHASE1
Trial Summary: This phase Ib trial tests the safety, side effects, and best dose of autologous anti-prostate stem cell antigen (PSCA)-chimeric antigen receptor (CAR)-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (PSC – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): City of Hope Medical Center
Acronym:

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

NCT Number: NCT05864144
Phase: PHASE1|PHASE2
Trial Summary: Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cem – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sensei Biotherapeutics, Inc.
Acronym:

Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers

NCT Number: NCT05519878
Phase: Not Applicable
Trial Summary: This clinical trial evaluates light therapy and occupational therapy in improving cancer related fatigue (CRF) patients with genitourinary cancers. Light therapy is a non-pharmacological and evidence- – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI)
Acronym:

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT Number: NCT05691465
Phase: Phase 2
Trial Summary: This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation (formed from cells that release hormones into the bloo – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

NCT Number: NCT05785741
Phase: Phase 1|Phase 2
Trial Summary: This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): DualityBio Inc.
Acronym:

Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments

NCT Number: NCT04705038
Phase: Not Applicable
Trial Summary: The purpose of this study is to learn how an educational intervention about orchiectomy as an alternative to medical castration for those who are already on medical castration will impact the number o – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Chicago
Acronym:

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT Number: NCT05800665
Phase: PHASE1
Trial Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also ide – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Genentech, Inc.
Acronym:

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

NCT Number: NCT03860272
Phase: Phase 1
Trial Summary: This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineere – clinicaltrials.gov for more information and locations and locations
Clinicaltrials.gov
Trial Sponsor(s): Agenus Inc.
Acronym:

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

NCT Number: NCT05605522
Phase: Phase 1
Trial Summary: This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fusion Pharmaceuticals Inc.
Acronym:

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

NCT Number: NCT05629494
Phase: Phase 4
Trial Summary: Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and ele – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Albany Medical College
Acronym: ADAPT-PSA

Improving Germline Testing in At-Risk Patients With Prostate Cancer

NCT Number: NCT05470036
Phase: Not Applicable
Trial Summary: A quality improvement initiative to improve rates of germline testing among men with prostate cancer through the use of an in-clinic educational sessi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of California, San Diego
Acronym: IMPRINT

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

NCT Number: NCT05413421
Phase: Phase 1
Trial Summary: The purpose of this study is to establish recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) and preliminary antitumor activity of ORIC-944 in patients with metast – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): ORIC Pharmaceuticals
Acronym:

Social Risk Factors and Discrimination in Cancer Survivorship

NCT Number: NCT05301114
Phase: NA
Trial Summary: The objective of the proposed study is to scale social risk factor screening and referral for cancer survivors and to solidify information exchange between clinical and community s – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Medstar Health Research Institute
Acronym:

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

NCT Number: NCT05168618
Phase: Phase 2
Trial Summary: This phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the bod – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Utah|National Cancer Institute (NCI)
Acronym:

A Study of NX-1607 in Adults With Advanced Malignancies

NCT Number: NCT05107674
Phase: Phase 1
Trial Summary: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignanci – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Nurix Therapeutics, Inc.
Acronym:

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer

NCT Number: NCT05053152
Phase: Phase 2
Trial Summary: This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Acronym: NRG PROMETHEAN

Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring

NCT Number: NCT05054296
Phase: Phase 2
Trial Summary: This phase II trial studies how well an exercise program and continuous Fitbit monitoring work for managing metabolic syndrome and cardiovascular disease risk in patients with pros – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Acronym:

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

NCT Number: NCT05036226
Phase: Phase 1|Phase 2
Trial Summary: The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydro – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Medical University of South Carolina
Acronym: COAST

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

NCT Number: NCT05011383
Phase: Phase 2
Trial Summary: This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): VA Office of Research and Development
Acronym: VA-BAT

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT Number: NCT05005728
Phase: Phase 2
Trial Summary: This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with me – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Xencor, Inc.
Acronym:

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

NCT Number: NCT04925284
Phase: Phase 1
Trial Summary: This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Exelixis
Acronym:

Improving Care After Inherited Cancer Testing

NCT Number: NCT04763915
Phase: NA
Trial Summary: The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genet – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Vanderbilt-Ingram Cancer Center
Acronym: IMPACT

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT Number: NCT04704505
Phase: Phase 2
Trial Summary: This is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic castration-resistant pros – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acronym: BAT-RAD

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT Number: NCT04691804
Phase: Phase 3
Trial Summary: To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Jiangsu HengRui Medicine Co., Ltd.
Acronym:

M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

NCT Number: NCT04633252
Phase: Phase 1|Phase 2
Trial Summary: Metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) are prostate cancers that have spread to other parts of the body. Use of the drug docetax – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Acronym:

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

NCT Number: NCT04606446
Phase: Phase 1
Trial Summary: This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Pfizer
Acronym: KAT6

Re-treatment 225Ac-J591 for mCRPC

NCT Number: NCT04576871
Phase: Early Phase 1
Trial Summary: The purpose of this study is to find out if re-treatment with 225Ac-J591 can be given without severe – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym:

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

NCT Number: NCT04506567
Phase: Phase 1|Phase 2
Trial Summary: The purpose of the initial (phase I) portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591 that can be given without severe side e – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Weill Medical College of Cornell University
Acronym:

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

NCT Number: NCT04478279
Phase: Phase 1|Phase 2
Trial Summary: This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in pati – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sapience Therapeutics
Acronym:

Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer

NCT Number: NCT04421222
Phase: Phase 1
Trial Summary: This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will recei – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): ESSA Pharmaceuticals
Acronym: EPI-7386

Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

NCT Number: NCT04353973
Phase: NA
Trial Summary: This study aims to determine if web-based eHealth delivery of pre-test and/or post-test counseling in cancer patients and/or those at risk for cancer can provide equal or improved – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Abramson Cancer Center at Penn Medicine
Acronym: eReach

Onco-primary Care Networking to Support TEAM-based Care

NCT Number: NCT04258813
Phase: NA
Trial Summary: The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Duke University
Acronym: ONE TEAM

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

NCT Number: NCT04038502
Phase: Phase 2
Trial Summary: This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): VA Office of Research and Development
Acronym: COBRA

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

NCT Number: NCT03866382
Phase: Phase 2
Trial Summary: This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that that has spread f – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:

Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors

NCT Number: NCT03880422
Phase: Not Applicable
Trial Summary: This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nu – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Roswell Park Cancer Institute
Acronym:

Study to Evaluate CCS1477 in Advanced Tumours

NCT Number: NCT03568656
Phase: Phase 1|Phase 2
Trial Summary: A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast can – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): CellCentric Ltd.
Acronym:

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

NCT Number: NCT02861573
Phase: Phase 1|Phase 2
Trial Summary: The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer ( – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Merck Sharp & Dohme LLC
Acronym:

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

NCT Number: NCT02769962
Phase: Phase 1|Phase 2
Trial Summary: Background: EP0057 consists of a sugar molecule cyclodextrin linked to a chemotherapy drug called camptothecin. The combined molecule or “nanoparticle drug conjugate” travels throu – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Acronym:

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can…

NCT Number: NCT02484404
Phase: Phase 1|Phase 2
Trial Summary: Durvalumab is a drug that may help people s immune systems respond to and kill cancer cells. Olaparib is a drug that may inhibit repairing DNA damage of cancer cells. Cediranib is – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Acronym:

Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer

NCT Number: NCT02016248
Phase: Not Applicable
Trial Summary: The purpose of this study is to determine the side effects and how effective CyberKnife stereotactic ablative body radiation (SABR) is in patients with prostate cancer. The CyberKn – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): MemorialCare Health System
Acronym:

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

NCT Number: NCT00588185
Phase: Not Applicable
Trial Summary: This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate c – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Memorial Sloan Kettering Cancer Center
Acronym:

Find Your Trial

Low Risk

Intermediate Risk

High Risk

Cancer Recurrence

Non-Metastatic Castration Resistant

Metastatic Castration Sensitive

Metastatic Castration Resistant

Study of AMG 509 in Subjects with Metastatic Castration-Resistant Prostate Cancer

This clinical trial is for patients who have metastatic castration resistant prostate cancer (mCRPC) and failed to respond to abiraterone acetate or enzalutamide (but not both) and to taxane-based chemotherapy.

This information is for educational purposes only and not intended as medical advice.
Patients should consult their medical doctor for advice and recommendations about specific clinical trials.

Pin It on Pinterest